Pancreatic Cancer Research

ResearcherSecond Affiliated Hospital of Zhejiang UniversityActive in the last 2 years

Xueli Bai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2934-0880; OpenAlex author ID A5044014447. Sources: OpenAlex.

Their work

Papers
44 (first author 3, last author 15)
Trials
0
Grants
0
Labs led
1
Collaborators
75
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 2 papers · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 3 papers · 2020: 5 papers · 2021: 3 papers · 2022: 3 papers · 2023: 9 papers · 2024: 6 papers · 2025: 6 papers · 2026: 3 papers

Papers 44

  1. Systemic Treatment Followed by Radical Resection Combined With Intestinal Autotransplantation for Locally Advanced Pancreatic Cancer: A Retrospectively Observa… First author DOI 10.1097/sla.0000000000006600↗
  2. Targeting SLC6A14-mediated nutrient competition reverses an immunosuppressive metabolic niche in pancreatic cancer. Last author DOI 10.1186/s40164-026-00818-9↗
  3. Immunochemotherapy for Borderline Resectable or Locally Advanced Pancreatic Cancer: A Randomized Controlled Trial. Co-author DOI 10.1200/jco-26-01393↗
  4. Lipid metabolism reprograming by SREBP1-PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy. Last author DOI 10.1002/cac2.70038↗
  5. Pancreatic cancer-derived extracellular vesicles enhance chemoresistance by delivering KRAS G12D protein to cancer-associated fibroblasts. Last author DOI 10.1016/j.ymthe.2025.01.023↗
  6. Targeting spermine metabolism to overcome immunotherapy resistance in pancreatic cancer. Last author DOI 10.1038/s41467-025-63146-2↗
  7. Elevated protein lactylation promotes immunosuppressive microenvironment and therapeutic resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci187024↗
  8. Correction: Phase 1b study of first-line fuzuloparib combined with modified FOLFIRINOX followed by fuzuloparib maintenance monotherapy in pancreatic adenocarci… Co-author DOI 10.1186/s12916-025-04078-y↗
  9. Reciprocal regulation of MMP-28 and EGFR is required for sustaining proliferative signaling in PDAC. Last author DOI 10.1186/s13046-025-03323-9↗
  10. Inhibition of DEF-p65 Interactions as a Potential Avenue to Suppress Tumor Growth in Pancreatic Cancer. Last author DOI 10.1002/advs.202401845↗
  11. Deciphering extracellular vesicles protein cargo in pancreatic cancer. Last author DOI 10.1016/j.bbcan.2024.189142↗
  12. Reprograming immunosuppressive microenvironment by eIF4G1 targeting to eradicate pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.xcrm.2024.101731↗
  13. Targeting cancer-associated fibroblast autophagy renders pancreatic cancer eradicable with immunochemotherapy by inhibiting adaptive immune resistance. Co-author DOI 10.1080/15548627.2023.2300913↗
  14. Phase 1b study of first-line fuzuloparib combined with modified FOLFIRINOX followed by fuzuloparib maintenance monotherapy in pancreatic adenocarcinoma. Co-author DOI 10.1186/s12916-024-03581-y↗
  15. 18F-FAPI-04 Outperforms 18F-FDG PET/CT in Clinical Assessments of Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.2967/jnumed.123.266283↗
  16. VG161 activates systemic antitumor immunity in pancreatic cancer models as a novel oncolytic herpesvirus expressing multiple immunomodulatory transgenes. Co-author DOI 10.1002/jmv.28108↗
  17. Multi-omics analysis reveals the chemoresistance mechanism of proliferating tissue-resident macrophages in PDAC via metabolic adaptation. Last author DOI 10.1016/j.celrep.2023.112620↗
  18. Protocol for isolating single cells from human pancreatic cancer tissues and analyzing major immune cell populations using flow cytometry. Last author DOI 10.1016/j.xpro.2023.102679↗
  19. Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-L1 immunotherapy. Last author DOI 10.1016/j.ymthe.2023.07.021↗
  20. Targeting MFAP5 in cancer-associated fibroblasts sensitizes pancreatic cancer to PD-L1-based immunochemotherapy via remodeling the matrix. Last author DOI 10.1038/s41388-023-02711-9↗
  21. Targeting ubiquitin-specific protease 8 sensitizes anti-programmed death-ligand 1 immunotherapy of pancreatic cancer. Last author DOI 10.1038/s41418-022-01102-z↗
  22. Siamese Delta Network with Multimodality Fusion for Systemic Treatment Response Prediction in Pancreatic Cancer. Co-author DOI 10.1109/embc40787.2023.10340012↗
  23. Normalization of tumor markers and a clear resection margin affect progression-free survival of patients with unresectable pancreatic cancer who have undergone… Co-author DOI 10.1186/s12885-023-10529-7↗
  24. Immune Checkpoint Neuropilins as Novel Biomarkers and Therapeutic Targets for Pancreatic Cancer. Co-author DOI 10.3390/cancers15082225↗
  25. Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy. Co-author DOI 10.1016/j.ebiom.2022.103958↗
  26. Adjuvant therapy with gemcitabine and stereotactic body radiation therapy versus gemcitabine alone for resected stage II pancreatic cancer: a prospective, rand… First author DOI 10.1186/s12885-022-09974-7↗
  27. Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy. Last author DOI 10.1186/s13046-022-02273-w↗
  28. Regulator of calcineurin 1 gene isoform 4 in pancreatic ductal adenocarcinoma regulates the progression of tumor cells. Co-author DOI 10.1038/s41388-021-01763-z↗
  29. NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1. Co-author DOI 10.1038/s41467-021-24769-3↗
  30. Identification of 2 Chinese Primary Pancreatic Ductal Adenocarcinoma Cancer Cell Lines and Their Phenotypes. Co-author DOI 10.1097/mpa.0000000000001932↗
  31. Genome-wide profiling of circulating tumor DNA depicts landscape of copy number alterations in pancreatic cancer with liver metastasis. Co-author DOI 10.1002/1878-0261.12757↗
  32. Oncolytic virotherapy in hepato-bilio-pancreatic cancer: The key to breaking the log jam? Co-author DOI 10.1002/cam4.2949↗
  33. Development of a Novel Multiparametric MRI Radiomic Nomogram for Preoperative Evaluation of Early Recurrence in Resectable Pancreatic Cancer. Co-author DOI 10.1002/jmri.27024↗
  34. The efficacy and toxicity of chemotherapy in the elderly with advanced pancreatic cancer. Co-author DOI 10.1016/j.pan.2019.11.012↗
  35. Patient-derived xenograft model engraftment predicts poor prognosis after surgery in patients with pancreatic cancer. Co-author DOI 10.1016/j.pan.2020.02.008↗
  36. Vimentin-positive circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patients with pancreatic cancer. Last author DOI 10.1016/j.canlet.2019.03.009↗
  37. Tumour cell-derived debris and IgG synergistically promote metastasis of pancreatic cancer by inducing inflammation via tumour-associated macrophages. Last author DOI 10.1038/s41416-019-0595-2↗
  38. Monitoring Tumor Burden in Response to FOLFIRINOX Chemotherapy Via Profiling Circulating Cell-Free DNA in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-17-1298↗
  39. Hypoxia-inducible factor-2α promotes tumor progression and has crosstalk with Wnt/β-catenin signaling in pancreatic cancer. Co-author DOI 10.1186/s12943-017-0689-5↗
  40. The hepatitis B virus X protein promotes pancreatic cancer through modulation of the PI3K/AKT signaling pathway. First author DOI 10.1016/j.canlet.2016.06.011↗
  41. OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo. Co-author DOI 10.18632/oncotarget.4579↗
  42. Inhibition of protein phosphatase 2A sensitizes pancreatic cancer to chemotherapy by increasing drug perfusion via HIF-1α-VEGF mediated angiogenesis. Co-author DOI 10.1016/j.canlet.2014.09.048↗
  43. Hypoxia-inducible factor 1α expression and its clinical significance in pancreatic cancer: a meta-analysis. Co-author DOI 10.1016/j.pan.2014.06.008↗
  44. Sister Mary Joseph's nodule as a first sign of pancreatic cancer. Co-author DOI 10.3748/wjg.v18.i45.6686↗

Closest collaborators

The 25 strongest of 75 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tingbo Liang · 38 shared papers, 2014–2026 · strength 5.75
  2. Xiaozhen Zhang · 14 shared papers, 2019–2026 · strength 2.28
  3. Lihong He · 10 shared papers, 2023–2026 · strength 1.86
  4. Mengyi Lao · 11 shared papers, 2020–2025 · strength 1.70
  5. Hanshen Yang · 10 shared papers, 2021–2025 · strength 1.70
  6. Kang Sun · 8 shared papers, 2023–2025 · strength 1.37
  7. Jiaqi Yang · 7 shared papers, 2017–2025 · strength 0.99
  8. Qi Zhang · 8 shared papers, 2016–2026 · strength 0.96
  9. Risheng Que · 8 shared papers, 2019–2026 · strength 0.94
  10. Yifan Hong · 4 shared papers, 2023–2025 · strength 0.84
  11. Lingyue Liu · 4 shared papers, 2022–2026 · strength 0.80
  12. Jian Xu · 5 shared papers, 2021–2024 · strength 0.73
  13. Xinyuan Liu · 3 shared papers, 2024–2025 · strength 0.70
  14. Jinyuan Song · 4 shared papers, 2022–2025 · strength 0.69
  15. Xiang Li · 6 shared papers, 2019–2023 · strength 0.66
  16. Xing Huang · 3 shared papers, 2021–2025 · strength 0.61
  17. Zhengtao Hong · 3 shared papers, 2022–2025 · strength 0.60
  18. Tingbo Liang · 3 shared papers, 2014–2026 · strength 0.49
  19. Guoliang Qiao · 2 shared papers, 2026 · strength 0.48
  20. Tianan Jiang · 2 shared papers, 2026 · strength 0.48
  21. Tao Ma · 5 shared papers, 2019–2021 · strength 0.47
  22. Xiang Li · 2 shared papers, 2024–2026 · strength 0.46
  23. Xinhui Su · 2 shared papers, 2024–2026 · strength 0.46
  24. Yi Duan · 3 shared papers, 2021–2023 · strength 0.44
  25. Tao Wei · 5 shared papers, 2017–2020 · strength 0.43

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.